Xu U Cao from 4808 River Crossing Ct, Ellicott, MD 21042, age 65

Resumes

Visiting Fellow

view source

Location:

Washington, DC

Industry:

Research

Work:

National Institutes of Health
Visiting Fellow

Professor

view source

Location:

Baltimore, MD

Industry:

Higher Education

Work:

Johns Hopkins University
Professor

Software Qa Automation Developer

view source

Position:

Sr. QA Engineer at Sony Pictures Entertainment, Senior Software QA Developer at Guthy-Renker

Location:

Los Angeles, California

Industry:

Entertainment

Work:

Sony Pictures Entertainment - culver city since Feb 2013
Sr. QA Engineer
Guthy-Renker - Los Angeles/Santa Monica Area since Apr 2012
Senior Software QA Developer
Bridgepoint Education - San Diego, CA Aug 2008 - Jan 2012
Software Developer
Gateway - San Diego Jul 2006 - Jun 2008
QA Developer

Education:

York University 2000 - 2003
Bachelor of Arts (BA), Information Technology

Skills:

Testing
Quality Assurance
Ruby
Ruby on Rails
APIs
REST
PHP
Web Applications
Selenium
Test Driven Development
Test Automation
Agile Methodologies
Scrum
Software Development
Unit Testing
XML
SDLC
QTP
Software Project Management

Languages:

Chinese

Xu Cao

view source

Isbn (Books And Publications)

Qing Zhu Wang Yunxi Jiao Shou Ba Shi Hua Dan Wen Ji

view source

Author
Xu Cao

ISBN #
7532540529

Us Patents

Interaction Of Smad6 With Hox Proteins And Uses Thereof
view source
US Patent:

6967078, Nov 22, 2005
Filed:

Aug 3, 2000
Appl. No.:

09/631411
Inventors:

Xu Cao - Birmingham AL, US
Xingming Shi - Birmingham AL, US
Shuting Bai - Birmingham AL, US
International Classification:

C12Q001/68
C07H021/04
C12N015/00
US Classification:

435 6, 435 691, 435 911, 536 231, 536 235
Abstract:

The present invention describes a novel interaction between Smad6 and the Hox genes in nuclear transcriptional regulation following BMP signal transduction. The present invention further provides methods of using this novel Smad6/Hox protein interaction to regulate gene expression, regulate bone formation and control osteoporosis. Further provided are methods of screening for compounds that interfere with the novel Smad6/Hox protein interaction, thereby resulting in expression of a Hox protein-repressed gene and/or stimulating bone formation.

Compositions And Methods For Improving Bone Mass Through Modulation Of Receptors Of Pth And Fragments Thereof
view source
US Patent:

8008074, Aug 30, 2011
Filed:

Mar 20, 2007
Appl. No.:

12/293713
Inventors:

Xu Cao - Birmingham AL, US
Assignee:

The UAB Research Foundation - Birmingham AL
International Classification:

C12N 5/00
A61K 38/00
A61K 38/18
A61K 38/29
C07K 14/00
US Classification:

435375, 514 88, 514 89, 514 118, 514 167, 435 71, 530350
Abstract:

The present invention relates to the discovery of novel receptors for the signaling of PTH and/or fragments of PTH, and the role of cPTH in bone development. The novel PTH receptors identified are selected from the group consisting of LRP5/6, TGFβRII, BMPRII (long form and short form), ActRIIA, and ActRIIB. Specifically, the present invention provides a novel screening tool for identifying compounds that improve bone mass by affecting certain pathways that promote or downregulate bone-forming activity. This promotion of bone-forming activity could provide for treatments for bone-loss or bone density disorders and/or kidney disease. The invention further encompasses the compounds, PTH ligands, and fragments of PTH ligands described herein; pharmaceutical compositions comprising the compounds, PTH ligands, or fragments of PTH ligand; and methods of increasing bone density using the compounds, PTH ligands, or fragments of PTH ligands.

Inhibition Of Binding Of Hox And Homeodomain-Containing Proteins And Uses Thereof
view source
US Patent:

20020082235, Jun 27, 2002
Filed:

Aug 31, 2001
Appl. No.:

09/943724
Inventors:

Xu Cao - Birmingham AL, US
Xingming Shi - Birmingham AL, US
Xiangli Yang - Birmingham AL, US
Assignee:

UAB Research Foundation
International Classification:

A61K048/00
C12N005/08
US Classification:

514/044000, 435/366000
Abstract:

The present invention demonstrates that BMP-2/4 activates osteopontin gene transcription by removing Hoxc-8 binding through Smad1 interaction with the Hoxc-8 DNA binding domain. Since the DNA binding domain is conserved in all Hox and homeodomain-containing proteins, Smad1 likely interacts with all Hox or homeodomain-containing proteins. Furthermore, the present invention reveals the Smad1-mediated transcriptional mechanism in the BMP-2/4 signaling pathway and also provides information about the transcriptional roles of the Hox genes during embryonic development.

Interaction Of Smad6 With Hox Proteins And Uses Thereof
view source
US Patent:

20060034843, Feb 16, 2006
Filed:

Sep 14, 2005
Appl. No.:

11/227664
Inventors:

Xu Cao - Birmingham AL, US
Xingming Shi - Birmingham AL, US
Shuting Bai - Birmingham AL, US
International Classification:

C12Q 1/68
A61K 39/395
A61K 48/00
A61K 38/17
US Classification:

424143100, 435006000, 514012000, 514044000
Abstract:

The present invention describes a novel interaction between Smad6 and the Hox genes in nuclear transcriptional regulation following BMP signal transduction. The present invention further provides methods of using this novel Smad6/Hox protein interaction to regulate gene expression, regulate bone formation and control osteoporosis. Further provided are methods of screening for compounds that interfere with the novel Smad6/Hox protein interaction, thereby resulting in expression of a Hox protein-repressed gene and/or stimulating bone formation.

Identifying Parathyroid Hormone Agonists And Antagonists
view source
US Patent:

20110256557, Oct 20, 2011
Filed:

Oct 30, 2009
Appl. No.:

13/127001
Inventors:

Xu Cao - Baltimore MD, US
Mei Wan - Baltimore MD, US
Erik Mills Schwiebert - Birmingham AL, US
Assignee:

DISCOVERYBIOMED, INC. - Birmingham AL
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:

G01N 33/566
US Classification:

435 723
Abstract:

Provided herein are methods of screening for an agent that is a PTH agonist or antagonist. For example, provided is a method of screening for an agent that is a PTH agonist or antagonist, the method comprising contacting a cell with LRP6 and the agent to be screened, wherein the cell comprises a PTH1R, and determining the level of LRP6 binding to the PTH1R. An increased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH agonist. A decreased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH antagonist. Also provided are methods of treating a skeletal disorder in a subject, wherein the skeletal disorder is characterized by proliferative bone growth or reduced bone density.

Modulation Of Gpcr-Mediated Camp Production Through Lrp6 And Its Therapeutic Application
view source
US Patent:

20120294871, Nov 22, 2012
Filed:

May 17, 2012
Appl. No.:

13/474200
Inventors:

Xu Cao - Baltimore MD, US
Mei Wan - Ellicott City MD, US
Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:

G01N 33/566
C12Q 1/48
A61K 31/713
C12Q 1/68
A61K 38/02
A61K 31/7088
A61K 39/395
C12Q 1/02
US Classification:

4241721, 435 721, 435 723, 435 15, 435 29, 435 613, 514 11, 514 44 R, 514 44 A
Abstract:

The present invention relates to low-density lipoprotein receptor related protein 6 (LRP6). More specifically, the present invention relates to targeting of LRP6 to modulate Gαactivity. In one embodiment, a method of screening for antagonists of IRP6-Gαinteraction comprises the steps of (a) contacting an agent that binds LRP6 with a cell; and (b) measuring the level of cAMP production in the cell in response to one or more GPCR ligands, wherein an agent that decreases cAMP production as compared to cAMP production in the cell not contacted with the agent identifies the agent as an antagonist of LRP6-Gαinteraction.

Inhibition Of Binding Of Hox And Homeodomain-Containing Proteins And Uses Thereof
view source
US Patent:

62844644, Sep 4, 2001
Filed:

Apr 5, 1999
Appl. No.:

9/286682
Inventors:

Xu Cao - Birmingham AL
Xingming Shi - Birmingham AL
Xiangli Yang - Birmingham AL
Assignee:

UAB Research Foundation - Birmingham AL
International Classification:

C12Q 168
C12N 1563
US Classification:

435 6
Abstract:

The present invention demonstrates that BMP-2/4 activates osteopontin gene transcription by removing Hoxc-8 binding through Smad1 interaction with the Hoxc-8 DNA binding domain. Since the DNA binding domain is conserved in all Hox and homeodomain-containing proteins, Smad1 likely interacts with all Hox or homeodomain-containing proteins. Furthermore, the present invention reveals the Smad1-mediated transcriptional mechanism in the BMP-2/4 signaling pathway and also provides information about the transcriptional roles of the Hox genes during embryonic development.

Compositions And Methods For Treating Disorders Characterized With Excessive Osteoclast Activity
view source
US Patent:

20230094597, Mar 30, 2023
Filed:

Sep 23, 2022
Appl. No.:

17/934937
Inventors:

- Baltimore MD, US
Xu Cao - Baltimore MD, US
International Classification:

A61K 38/47
C07K 16/28
A61P 19/08
Abstract:

Provided herein are compositions and methods directed to treating, delaying progression of, or reducing cancer growth or metastasis, and the severity of disorders characterized with increased osteoclast activity through hindering and/or inhibiting osteoclastogenesis and/or osteoclast activity. In particular, the present invention provides compositions and methods directed to hindering and/or inhibiting Siglec15 and sialylated TLR (e.g., TLR2, TLR4) interaction by specific sialyltransferases.